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Abstract 
  
Smith-Magenis Syndrome (SMS) is a human genetic disorder that is caused by 
either a deletion within chromosomal region 17p11.2 or a mutation of a gene in that 
region –the RAI1 gene. The most prominent phenotypes observed with this disorder are 
mental retardation, distinctive craniofacial features, and sleep disorders caused by an 
inverted pattern of serotonin secretion. The current methods for molecular detection of 
Smith-Magenis Syndrome are reliable for the detection of the deletions within 
chromosomal region 17p11.2, but are not reliable in detecting mutations with the RAI1 
gene. One way to enhance the detection of RAI1 mutations is with the use of Single 
Nucleotide Polymorphisms (SNPs). SNPs are discrete polymorphisms within the genome 
of individuals that allow for a high resolution map of the genome to be constructed.  This 
map can then be used in order to determine if there are particular SNPs associated with 
particular human disorders.  If there are, then the SNPs can be used for diagnosis of these 
disorders.  The goal of this research project was to determine if there are any SNPs 
prominently associated with SMS patients.  This method may lead to an improved 
diagnosis for patients with phenotypes associated with SMS, but do not have a deletion of 
DNA in the appropriate region of chromosome 17. Detection of abnormalities utilizing 
SNPs may also help individuals with other genetic disorders as well.  
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Introduction  
 
Smith-Magenis Syndrome (SMS) is a human genetic disorder that is believed to 
be caused by haploinsuffiency of the RAI1 gene which can lead to mental retardation and 
multiple congenital anomalies that are apparent at birth.  The anomalies that appear after 
birth include distinctive craniofacial and skeletal features, infantile hypotonia, 
neurobehavioral problems, and sleep disorders caused by an inverted pattern of serotonin 
secretion.  The phenotypes associated with SMS become more prominent and 
recognizable with age [7].  The developmental delays, neurobehavioral difficulties and 
sleep disturbances associated with Smith Magenis Syndrome may cause an initial 
misdiagnosis because of the similar phenotypes found in patients with autism, Prader-
Willi syndrome, Down syndrome, velocardiofacial syndrome, Fragile X, or Angelmans 
syndrome. The published prevalence of SMS is 1/25,000 births, but is felt to be 
underestimated and closer to 1/15,000 birth because of misdiagnosis [8].  SMS, however, 
is a distinct genetic disorder that is caused by either a deletion of chromosomal region 
17p11.2 or a mutation within one gene in that chromosomal region, the RAI1 gene. At 
this time it is unknown and more research is needed to determine whether SMS is caused 
by de-novo mutations in the patient or parental mosaicism. As of 2007, only one case 
with parental mosaicism was documented; the rest resulting from de-novo mutations 
within the RAI1 gene [7]. Currently, the only method available for the detection of a 
mutation within the RAI1 gene is direct sequencing of the gene. The distinction and 
correct diagnosis between clinically similar disorders by laboratory analysis not only 
improves the treatment of the patient, but also improves the understanding of the factors 
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causing the disorders. The objective of this project is to utilize Single Nucleotide 
Polymorphisms (SNPs) to further improve the detection of Smith-Magenis Syndrome by 
identifying prominent genetic markers that are associated with the disorder. Even in the 
case of de-novo mutations, the SNP profile of the patient may help evaluate the 
progression and/or severity of the disease (Zies, Pers. Comm) 
Current research indicates that the RAI1 gene plays a role during transcriptional 
regulation, but additional studies are needed to fully assess the function of the protein. 
The disease phenotype results from haploinsufficiency due to either an interstitial 
deletion of the gene or an intragenic mutation causing a nonfunctional gene product. Of 
the six exons composing RAI1, the mutations on the third exon are of the most interest 
because they are the only mutations known to be responsible for the phenotypes observed 
in SMS patients. At this point, the only known SNPs found in the third exon include: 
G269C, G493A, G837A, G1992A, G3183A, T4311C, G4530T, G5334A, and T5601C 
[7].  
The detection of the interstitial deletion that does not cause changes in the 
terminal ends of chromosome 17p11.2 can be identified by G-band cytogenetic analysis 
or through fluorescence in-situ hybridization (FISH), this includes the large 3.5Mb 
deletion that is associated with approximately 70% of SMS patients. Giemsa stain is used 
in G-band analysis to chemically produce differentially stained regions on chromosomes 
[9]. Utilizing cytogenetic analysis, the common 3.5Mb SMS deletion can be observed 
visibly using conventional G-banded analysis [8]. An additional 20% of SMS cases 
contain a smaller deletion within the same chromosomal region that can be detected by 
FISH analysis.  
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There are two different types of FISH analysis that are used during different 
phases of mitosis: FISH metaphase and FISH interphase. FISH-metaphase is the most 
prevalent because it allows the location of the gene on the chromosome to be determined 
through the hybridization of fluorescently labeled probe onto denatured DNA that is 
condensed into the recognizable chromosomes. Using a fluorescent light, fluorescence of 
the condensed chromosome shows normal regions of the condensed chromosomes. The 
absence of a particular region of fluorescence signifies a deletion within the chromosome. 
While FISH-interphase allows for the rapid detection of certain deletions, duplications, 
and other abnormalities, it does not allow for the visualization of the labeled probe on 
specific chromosomes as they are not condensed during interphase [2]. FISH analysis is 
currently the most widespread method used to detect deletions and duplications causing 
genetics disease. It is a common and reliable genetic test in the detection of Down, Patau, 
and Edwards syndromes because these disorders involve whole chromosome duplications 
or deletions. However, this type of analysis is not as reliable for partial deletions and 
duplications that are associated with SMS. In addition to the fact that this method focuses 
on large scale changes in the chromosomes, it is very labor intensive, at risk for 
misdiagnosis, and less adaptable to automation [5].   
If a patient has a mutation instead of a deletion, it cannot be detected by G-band 
cytogenetic analysis or by FISH analysis.  For known genes, the only method currently 
available for the detection of mutations is to sequence the gene responsible for the 
disorder.  All of the known genetic mutations which cause SMS are located within the 
third exon and each mutation is unique.  Individuals with mutations within the RAI1 gene 
have similar SMS phenotypes as seen in individuals with deletions in 17p11.2, but also 
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have a short stature, hearing loss, and organ anomalies [7]. While RAI1 is responsible for 
the phenotypes associated with SMS, more research is needed to understand the function 
and role of the gene in causing SMS. It is possible that other genes may play a role in the 
phenotype variability observed in patients with SMS.  An improved method of detection 
for genetic disorders may help sort out phenotypes, eliminate misdiagnosis, and 
ultimately lead to a better understanding of the genetic disorder.    
The improvements in genetic analysis allow for a more thorough investigation 
into the causes of many heritable diseases, including SMS. Prior to the advancements in 
genetic testing, a doctor was without a definitive answer into the fundamental cause for a 
genetic disease. However, the recent completion of the human genome project enables a 
more thorough understanding of the causes behind genetic disorders. Whole genome 
analysis, such as G-band analysis and FISH analysis, constructs a low resolution map of 
the genome and allows for the detection of large scale deletions or duplications that may 
be causing the particular disorder. However, instead of sequencing the whole gene to find 
errors in the new patient DNA, single nucleotide polymorphisms (SNPs) analysis could 
construct a higher resolution map and allow for the detection of smaller changes in the 
genome that may cause genomic disorders.  
Single nucleotide polymorphisms (SNPs) are single base differences that cause 
variation in DNA sequence within the normal population.  These single base changes are 
not usually the cause of a genetic disease, but instead are used primarily as biological 
markers to pinpoint disease causing loci [6]. They are similar to the previously used 
microsatellites which cause variations within a particular gene locus, but are stable 
changes and do not cause additional errors by the DNA polymerase.  SNPs have become 
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the markers of choice in genetic analysis because of their high frequency in the human 
genome and their amenability to automation. SNPs within a coding region are of special 
interest to researchers because of their direct effects on the function of the protein. [4] 
The change in protein can be directly associated with the observed phenotype for a 
particular genetic disorder. However, because only 2 percent of a person’s DNA accounts 
for the coding region, most SNPs are found in regulatory regions outside of the coding 
sequences. If a gene includes the coding region and 10 kb upstream, then 98% of all 
genes will have a SNP within 5 kb of the gene and 93% of all annotated genes have a 
SNP within the gene [6].  
Most genetic diseases are not caused by a sole gene, but by complex interactions 
and linkage between multiple genes.  Linkage disequilibrium (LD) describes the 
relationship between two alleles that tend to be inherited together more than predicted or 
more often than other possible allele combinations. Linkage disequilibrium can be found 
between the disease-causing region and nearby SNP genetic markers. The linkage 
between SNPs on a particular chromosome is called a haplotype and can be used in the 
identification of a disease-causing locus. [6] The SNP approach enables the construction 
of a dense map of polymorphic markers that can be used in a systematic scanning of the 
genome for regions associated with disease without having to sequence large regions [1]. 
SNP analysis can also be used to investigate the presence of disease-causing loci in a 
given population. For example, the use of SNPs to map the genes causing Crohn’s 
disease in individuals with European descent allowed for a better understanding of the 
linkage disequilibrium correlating to disease status [6]. The improvement in SNP analysis 
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leads the way not only to the detection of genetic diseases, but also to improvements in 
drug development [4].  
The genetic variations due to SNPs result in the factors that contribute to the 
genetic predisposition to diseases, drug addictions, and responses to pharmaceutical 
interventions. The new and expanding field of pharmacogenomics not only focuses on 
the genes that metabolize the particular gene, but also drug transporters, receptors, and 
signaling pathways.  SNPs will allow a more personalized healthcare in which a patient’s 
treatment will be adapted to work optimally depending upon their genome. .  
The goal of this experiment was to develop a higher resolution analysis using 
Single Nucleotide Polymorphisms (SNPs) to ultimately improve the detection of non-
deletion Smith-Magenis Syndrome cases. An analysis of the sequenced regions of known 
cases was performed to quantify the common SNPs that are associated with the non-
deletion SMS patients. A bioinformatic study  investigated the prevalence of particular 
phenotypes associated with specific SNPs, and was expanded by adding a new SMS case 
in an effort to further improve the statistics found originally in the bioinformatic study. 
The findings of the project will contribute to improvements in the methods of detection 
for SMS and increase the ability to determine the severity of the phenotypes that will 
appear during the life of the patient. The results of the study will also lay the groundwork 
for the detection of other genetic disorders using SNPs.  
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Methods  
 
Pivot Table 
 A pivot table was generated to compile the patient data in a manner that 
allows the distribution of phenotypes to be matched to the SNPs found in the SMS 
patients. The original patient data was initially organized by entering the patient data 
from information sheets obtained from the Elsea laboratory at VCU. Each patient 
information sheet identified all of the SNPs found in the genomic DNA of each SMS 
patient as well as the SNP ID and corresponding amino acid change for each SNP. The 
SNP ID represents an “rs” number, such as SNPrs3818717, which can be entered at the 
NCBI website to perform a reference cluster search to identify specific information about 
each SNP.  A separate table was created and named “SNP” in the spreadsheet which 
matched the amino acid change and the SNP ID to the corresponding nucleotide change. 
Using a function in EXCEL called VLOOKUP that referenced the “SNP” table, the 
nucleotide changes and the corresponding amino acid change were automatically filled in 
for each corresponding SNP found in the patient.  
The Elsea laboratory also provided a list of phenotypes observed for each patient. 
This table was named “Phenotype” and was used as a reference table for the subsequent 
tables. A formula was derived using the VLOOKUP function that allowed the given 
phenotypes of a patient to automatically be matched to the SNP of each patient. The 
observed patient phenotypes would now be matched with the corresponding SNPs, 
eliminating the individual patient data and compiling the data based solely on SNPs and 
phenotypes. The phenotypes were given a number 1 -4. The number “1” meant the 
phenotype was present, “2” meant the phenotype was absent, “3” meant non-applicable 
because of sex or age, and “4” meant missing information. A table was then created that 
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used the “IF” function in an EXCEL equation. The table looked at the previously 
compiled table for phenotypes corresponding to particular SNPs and looked for any 1 
(meaning they had the phenotype). A 1 would be put in its place on the new table. If there 
were any other numbers, then a 0 would be entered—meaning they did not have the 
particular phenotype. A pivot table was created that consolidated the number of patients 
who had a “1” for the given nucleotide change. It tallied up the number of times a 
particular phenotype was observed for a patient with the nucleotide change. As a result, a 
table was created that contained the 13 observed SNPs and the number of times a 
particular phenotype was detected for each single nucleotide change. The frequency of 
phenotypes observed for a nucleotide change was calculated by: 
𝐹𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑜𝑓 𝑆𝑁𝑃 𝑓𝑜𝑟 𝑎 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑤𝑖𝑡ℎ 𝑎 𝑆𝑁𝑃 𝑓𝑜𝑟 𝑔𝑖𝑣𝑒𝑛 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑁𝑃𝑠 𝑓𝑜𝑟 𝑔𝑖𝑣𝑒𝑛 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒  
 
This allowed for the visualization of the distribution of nucleotides that correlate 
with the observed phenotypes in the non-deletion, non-mutation cases of SMS. Despite 
the total number of frequencies for a given phenotype, the frequencies of SNPs could be 
compared on an even level. Any phenotypes without corresponding SNPs were deleted 
from the pivot table because they held no significance to the values in the pivot table.  
Polymerase Chain Reaction 
 
 PCR reactions were used to amplify short, overlapping DNA fragments that can 
be sequenced to determine the complete sequence of exon 3.  Each primer set, its product 
size, and annealing temperature can be found in Table 1. The PCR reactions with the 
same annealing temperatures were put into the thermo cycler at the same time.  The 
optimal conditions of the PCR reactions for each primer were determined through a series 
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of PCR reactions that altered DNA concentrations, primer concentrations, and Bovine 
Serum Albumin (BSA). BSA is used to help stabilize enzyme activity during the 
reactions. The final concentrations of PCR components used in the mastermix was: 1x 
PCR Buffer, 1.5mMMgCl2,  0.4mM dNTP, 1unit GoTaq® polymerase (Promega, Inc.), 
4.0ng/μL DNA (VCU),  0.4mM upstream primer (VCU), 0.4mM downstream primer 
(VCU), and dH2O to the appropriate volume. The PCR cycle conditions used the 
following temperatures:  
 
 
 After each PCR reaction, gel electrophoresis was performed in order to determine if each 
PCR was successful and the expected band size was obtained. In initial PCR reactions of 
25μL total volume, 17uL of PCR product and 5uL dye were used to determine successful 
PCR reactions. The final volume of the PCR product during preparation for sequencing 
varied and was dependent on downstream needs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Temperature Time 
 94°C 5:00 
 94° 1:00 
 Annealing 1:00 (60,62,64,or 66ºC, depending on the primer) 
72° 1:00 *repeated 35x 
72° 10:00 
 4° Hold 
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Primer Set Primers 
Product Size 
(bp) Annealing Temperature (°C) 
1 SHE 505/506 925 60 
2 SHE 507/508 947 62 
3 SHE 509/510 995 64 
4 SHE 511/512 861 66 
5 SHE 513/514 910 62 
6 SHE 515/516 1010 64 
7 SHE 335/336 964 60 
8 SHE 339/340 887 60 
9 SHE 527/528 362 62 
10 RA 45/46 310 64 
 Table 1: PCR Reaction Preparation- Each of the ten primer sets had two primers, each 
with a different expected product size. The PCR reactions with the same annealing 
temperatures were performed at the same time.  
 
ExoSAP-IT 
 
 Prior to DNA sequencing, the PCR downstream products were cleaned up to 
remove contaminating primers and dNTPs through the use of ExoSAP-IT® (USB 
Corporation). In the ExoSAP-IT® reaction, 2.0μL of ExoSAP-IT® is added to 5.0μL of 
PCR product and heated at 37°C for 15 minutes and then 80°C for 15 minutes. Cleaned 
PCR products (7.0μL) and appropriate primers (2μL of 20mM primer and 8μL dH2O) 
were sent for sequencing at VCU sequencing core facility or ACGT, Inc.  
DNA Sequencing  
The purpose of DNA sequencing is to determine the genetic code found in the PCR 
products from the SMS and genomic DNA samples. Once the sequences from each PCR 
product are identified, they can be matched together creating the sequence for the entire 
region of interest (Exon 3). The sequences from both the normal and SMS 358 patient are 
compiled and the sequence from them aligned to a search query on the NCBI website for 
RAI1 exon 3.  The alignment compares the bases from the two sequences and shows any 
differences.  In this manner, SNPs can be identified.  SNPs that are found during the 
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alignment analysis can then be added to the database with the corresponding phenotypes 
observed in the patient. 
Initially, sequencing products were produced for sequencing at the VCU sequencing 
core facility from cleaned EXO-SAPIT products. The reactions sent to the VCU facility 
for sequencing are found in Table 2.  
Sequence Reaction Primer PCR Reaction 
1 SHE 507 3 
2 SHE 507 4 
3 SHE 513 9 
4 SHE 513 10 
5 SHE 527 17 
6 SHE 527 18 
 Table 2: Sequencing Reactions Sent to VCU Sequencing Core Facility - Six 
reactions were sent to the sequencing core facility at VCU as an initial analysis of the 
DNA sequencing.  
 
DNA sequencing at UMW was performed according to the procedures found in the 
Beckman Coulter GenomeLab Dye Terminator Cycle Sequencing with Quick Start Kit. 
The first step in the preparation of the DNA sequencing of the reaction was to add 8.0µL 
of DTCS Quick Start Master Mix, 2.0µL of sequencing primer, 3.0µL of DNA Template, 
and 7.0µL of dH20 into each tube. The DNA template was formed in the PCR reactions 
and the corresponding PCR reaction and primers can be seen in Table 3. A control was 
made using the supplied control template and primers. The sequencing reactions 
underwent thermal cycling program which consisted of 30 cycles of 96ºC for 20 seconds, 
50ºC for 20 seconds, and 60ºC for four minutes followed by a hold at 4ºC. Following the 
thermal cycle reactions, a Glycogen stop solution was freshly made and added to each 
reaction. The reactions then went through an ethanol precipitation reaction. The formed 
pellet was dried and resuspended in Sample Loading Solution. The samples were 
transferred into a sample plate and placed into the CEQ Machine for DNA Sequencing.  
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Five unsuccessful attempts at sequencing were performed using both the normal and 
patient DNA samples using the CEQ machine at the University of Mary Washington. The 
last failed attempt at DNA sequencing used all of the successful PCR reactions in 
addition to the corresponding SHE primers for each reaction. The DNA sequencing 
reactions were performed by adding the constituents according to the information found 
in Table 3.  
Sequence Reaction Primer PCR Reaction 
1 SHE 505 1 
2 SHE 505 2 
3 SHE 506 1 
4 SHE 506 2 
5 SHE 508 3 
6 SHE 508 4 
7 SHE 509 5 
8 SHE 509 6 
9 SHE 510 5 
10 SHE 510 6 
11 SHE 514 9 
12 SHE 514 10 
13 SHE 335 13 
14 SHE 335 14 
15 SHE 336 13 
16 SHE 336 14 
17 SHE 339 15 
18 SHE 339 16 
19 SHE 340 15 
20 SHE 340 16 
21 SHE 528 17 
22 SHE 528 18 
23 RA 45 19 
24 RA 45 20 
25 RA 46 19 
26 RA 46 20 
Table 3: Sequence Reaction Preparation-The 26 DNA sequencing reactions utilized the 
DNA fragments created by successful PCR reactions in both normal and patient samples. 
The forward and reverse primers were used in the sequencing for both the normal and 
patient DNA samples.  
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The sequencing reactions in Table 3 were also sent to ACGT, Inc. for sequencing. 
The sequence data files were accessed through an internet portal and the chromatograms 
were converted to genetic sequence. The sequences from the VCU Core Facility and 
ACGT, Inc. were then analyzed by aligning the sequences against the accession number 
for RAI1, NM_030665.3. Alignment of the DNA allowed for any SNPs to be identified 
between the subject and the query search for both normal and SMS patient 358. 
Modifications to the original Pivot Table  
After the SNPs were identified, they were inserted into the pivot table using the 
same method in the initial setup of the pivot table. A new pivot table was generated and 
the enhanced pivot table by adding patient SMS 358 was observed and compared to the 
original pivot table.  
 In addition to the pivot table showing all of the phenotypes with corresponding 
SNPs, the phenotypes were grouped into 24 large, common phenotype categories. The 
grouped phenotype categories can be found in Appendix C in addition to the full length 
name for each abbreviation in the pivot table. Appendix C also contains the phenotypes 
that were rare and not grouped. In this pivot table, the number of patients observed with a 
particular grouped phenotype was determined by finding the highest number of SNPs for 
any one phenotype in the group.  
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Results 
 
Analysis of SNP data from previously sequenced patients. 
In the initial analysis of patient data, there were 53 patients profiles entered into 
the database and 13 different SNPs found in the patient population. A total of 174 SNPs 
were found in the initial patient population. A frequency table of observed SNPs was 
created and can be found in Table 1.  
SNP 
Number of 
Patients Observed 
Frequency of SNP 
in SMS Patients 
A3634G 1 1.9 
A4685G 1 1.9 
A5178T 5 9.4 
C4530T 2 3.8 
C493A 29 54.7 
G1867A 1 1.9 
G1992A 40 75.5 
G269C 28 52.8 
G3183A 1 1.9 
G4512T 1 1.9 
G5423A 1 1.9 
G837A 27 50.9 
T5601C 37 69.8 
Table 1: Number and Frequency of SNPs found in the Initial Patient Population- 
The frequency of the SNP in the SMS patient population was calculated by dividing the 
number of patients with a particular SNP by the total number of patients in the 
population. The frequency of SNPs observed in this study was compared to the average 
of the SNP in the normal population.  
  
The SNP with the highest frequency in the patient population was G1992A 
followed by C493A and G296C. Many of the SNPs were only observed in one patient of 
the population. The original pivot table is found in Appendix B and was used to observe 
the correlation between SNPs and phenotypes in the patient population. The full names to 
the abbreviations found in Appendices B and C can be found in Appendix A. The pivot 
table in Appendix C examines the percentage a particular SNP is found for a given 
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phenotype. The patterns observed in both Appendices A and B are similar to the SNP 
frequencies observed in Table 1.  
 
PCR and Gel Electrophoresis 
During the PCR fragment preparation, adjustments of the mastermix were needed 
for the primers to work well for all the PCR reactions. The addition of 1.0μL of BSA 
(reducing dH2O to 13.25μL) in some reactions was needed after they were unsuccessful 
using the initial mastermix. Doubling the amount of genomic DNA and both primers 
gave more consistent data when observed on gels. 
The PCR products from the PCR reactions were examined by gel electrophoresis 
to determine if a successful reaction was performed. Each primer set had an expected size 
and using standard bands on the ladder, the bands on the gel could be compared to 
determine the size of each band. The predicted size of each band can be found in Table 4 
and can be compared to the expected size of each band. Reactions 8A, 1B (both from 
primer set SHE 509/510) were unsuccessful as well as reactions 5B and 6B (SHE 
515/516).  
 
 
Figure 1: Gel Electrophoresis of PCR Reactions for Normal and Patient DNA Samples- 
Gel Electrophoresis allows the size of the PCR products to be compared to standard DNA 
fragments found on the ladder. Figure 1A has reactions 1-7, 1B reactions 8-14, and 1C 
reactions 15-20. Each gel contains a ladder in the first well as a means of comparison. 
The corresponding reaction for each lane can be found in Table 1 along with the 
predicted size of each band.  
A                                                                         B                                                                         C 
    1     2      3     4    5    6     7      8           1      2    3     4      5      6     7      8         1     2     3    4     5      6      7      8       
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Lane Primer DNA Type Estimated Size (bp) Expected Size (bp) 
1a Ladder       
2a SHE 505/506 Normal 940 925 
3a SHE 505/506 Patient 940 925 
4a SHE 507/508 Normal 935 947 
5a SHE 507/508 Patient 935 947 
6a SHE 509/510 Normal 1000 995 
7a SHE 509/510 Patient 1000 995 
8a SHE 511/512 Normal Unsuccessful 861 
1b Ladder   
 
  
2b SHE 511/512 Patient Unsuccessful 861 
3b SHE 513/514 Normal 875 910 
4b SHE 513/514 Patient 875 910 
5b SHE 515/516 Normal Unsuccessful 1010 
6b SHE 515/516 Patient Unsuccessful 1010 
7b SHE 335/336 Normal 825 964 
8b SHE 335/336 Patient 825 964 
1c Ladder   
 
  
2c SHE 339/340 Normal 840 887 
3c SHE 339/340 Patient 840 887 
4c SHE 527/528 Normal 350 362 
5c SHE 527/528 Patient 350 362 
6c RA 45/46 Normal 305 310 
7c RA 45/46 Patient 305 310 
8c Empty       
Table 1: Results from Gel Electrophoresis -Table 1 was compiled from the data observed 
in Figure 1. The size of each band was predicted from a comparison to the ladder in each 
gel. Both Normal and Patient DNA were compared in the gels.  
 
The successful PCR reactions that produced bands in the gel were accurate when 
compared to the ladder and the expected size of the PCR product. Reactions involving 
SHE 511/512 and SHE 515/516 were unsuccessful and did not produce bands on the gel 
comparable to the expected size of the PCR product. The successful reactions could be 
sequenced. During failed attempts at sequencing at UMW, the same PCR products were 
cleaned and sent to sequencing core facilities to be sequenced. After the successful 
sequencing of the normal and patient DNA products at the sequencing core facilities, the 
sequences were aligned against a known search query on the NCBI website for Exon 3. 
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After the alignment and identification of SNPs within the patient DNA, the SNPs in the 
patient DNA were compared to known SNPs within Exon 3. The highlighted regions in 
Figure 1 represent the DNA that has been sequenced and also shows which regions 
remain to be sequenced. The SNPs within the regions were identified and marked in 
Figure 1 as well as reported in Table 2 and 3.   
The DNA sequencing of the six PCR fragments done at the VCU sequencing core 
facility discovered one SNP in the SMS 358 patient DNA using the PCR fragment from 
reaction 18 and the primer SHE 527. The SNP was not observed in the normal DNA and 
no other SNPs were found in any of the other PCR fragments using the corresponding 
primer for each.  
Figure 1: Sequenced Exons from RAI1 
Exon 3 
 
gcgggggagc aggcagggtg gggaggtggg tgggcgggcg ctttctgagg caaaaggaag SHE323 
tggcccgtct gaatcgctca tcctctgccc cctccctgcc catcctcccc tccctccttc  
cctccctccc tcccttcctt tttcttttca cagataacca gcccgagtca tgcagtcttt start E3 
tcgagaaagg tgtggtttcc atggcaaaca acagaactac cagcagacct cgcaggaaac  
atcacgccta gagaattaca ggcagccgag tcaggccggg ctaagctgcg accggcagcg  
gctgctcgcc aaggactatt ataacccgca gccttacccg agctatgagg gtggcgctgg  
cacgccctct ggcactgcag ccgcggtggc cgccgacaag taccaccgag gcagcaaggc  
cctgcccaca cagcaaggcc tgcaggggag gccggctttc cctggctacg gcgtccagga SNP G269C 
cagcagcccc tacccaggcc gctatgctgg tgaggagagc cttcaggctt ggggggcccc  
acagccacca cccccacagc cgcagccact acctgcaggg gtggccaagt atgatgagaa  
cttgatgaaa aagacagcag tgccccccag caggcagtat gcagagcagg gcgcccaggt  
gccctttcgg actcactccc tgcacgtcca gcagccaccg ccgccccagc agcccctggc SNP C493A 
ataccccaag ctccaaaggc agaagctgca gaacgacatt gcctcccctc tgcccttccc  
ccagggtacc cactttcctc agcattccca gtccttcccc acctcctcca cctactcctc  
ctctgtccag ggtggtgggc agggggccac tcctataaga gttgcacagc accgactgcc  
cagccccatg acaggccgct gactgccagc tccagcctgg ccccggggca gcgggtccag  
aatcttcatg cctaccagtc gggccgcctc agctatgacc agcagcagca gcagcagcag SNP G837A 
cagcagcagc agcagcagca agcccttcag agccggcacc atgcccagga aaccctccat 
taccaaaacc tcgccaagta tcagcactac gggcagcaag gccagggcta ctgccagccg  
gacgcagccg tccggacccc agagcagtac taccagacct tcagccccag ctccagccac  
tcacccgccc gctccgtggg ccgctcacct tcctacagtt ccacaccgtc gccgctgatg  
ccaaacctgg agaactttcc ctacagccag cagccgctca gcaccggggc cttccccgca 
gggatcactg accacagcca cttcatgccc ctgctcaatc cctccccaac ggatgccacc  
agctctgtgg acacccaggc tggcaactgc aagccccttc agaaggacaa gctccctgag  
aacctgctgt cggatctcag cctgcagagcc tcacggcgct gacctcacag gtggagaaca  
tctccaacac cgtccagcag ctgctgctct ccaaggctgc tgtgccgcag aagaaaggtg  
tcaagaacct cgtgtccagg accccagagc agcataaaag ccagcactgc agccccgaag  
ggagcggcta ctcagccgag cccgcaggca caccgctgtc agagccgccg agcagcacgc  
SHE505
 
SHE507
 SHE506 
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cacagtccac gcatgcggag ccgcaggagg ccgactacct gagcggctcc gaggacccac  
tggagcgcag cttcctctac tgcaaccagg cccgtggcag ccctgccagg gtcaacagca  
actcgaaggc caagcccgag tccgtgtcca cctgttctgt gacctctcct gacgacatgt SHE508R 
ccaccaaatc tgacgactcc ttccagagcc tacacggcag tctgccgctc gacagcttct  
ccaagttcgt ggcgggtgag cgggactgtc cgcggctgct gctcagcgcc ctggcacagg  
aggacctggc ctccgagatc ctggggctgc aggaagccat cggtgagaag gccgacaaag  
cttgggctga agcacccagc ctggtcaagg acagcagcaa gccacccttc tcgctggaga  
accacagcgc ctgcctggac tctgtggcca agagtgcgtg gccccggcct ggggagccgg SNPG1992A 
aggccctgcc cgactccttg cagctggaca agggcggcaa tgccaaggac ttcagcccag  
ggctgtttga agacccttcc gtggccttcg ctacgcctga ccccaaaaag acaactggtc  
ctctctcctt tggtaccaag cccacccttg gggttcctgc tccagacccc actacagcag 
cttttgactg tttcccggac acaaccgctg ccagctcagc ggacagcgcc aacccctttg  
cctggccaga ggaaaacctg ggggatgctt gtcccaggtg gggattgcac cctggcgagc  
ttaccaaggg cctggagcag ggtgggaagg cctcagatgg catcagcaaa ggggacaccc  
atgaggcttc ggcctgcctg ggcttccagg aggaggaccc ccctggggag aaggtggcct  
cgttgcccgg ggacttcaag caggaggagg tgggtggggt gaaggaggag gcaggtgggc  
tgctgcagtg ccccgaggtg gccaaggctg accggtggct ggaggacagc cggcactgct  
gttccaccgc cgacttcggg gacctcccac tgctgccacc caccagcagg aaggaggacc SHE511F 
tggaagctga ggaggagtac tcctccctat gtgagctcct gggcagcccc gagcagaggc  
ctggcatgca ggacccgctg tcacccaagg ccccactcat ctgcaccaag gaggaggtgg 
aggaggtgct ggactccaag gccggctggg gctctccgtg ccacctctca ggggagtccg 
tcatcctgct gggccctaca gtgggcaccg agtcaaaggt ccagagctgg tttgagtcct 
ctctgtcaca catgaagcca ggtgaagagg ggcctgatgg ggagcgagct ccaggggatt 
ccaccacctc ggacgcctct ctggcccaga agcccaacaa gcctgctgtg cccgaggcgc  
ccatcgcaaa gaaagagcct gtgccacggg gcaaaagctt acggagccgt cgggtgcacc 
gggggctgcc cgaggccgag gactccccat gcagggcacc agtgctgccc aaagacctct  
tgctccctga atcctgcaca gggccccccc agggacagat ggaaggggct ggagccccag 
gccggggggc ctcggaaggg ctccccagga tgtgtactcg ttctctcacg gccctgagtg SNP  
agccccgcac gcccggaccc ccaggcctga ccaccacccc tgcaccccca gacaaactgg  
ggggcaagca gcgagccgcc ttcaagtcgg gcaagcgggt ggggaagccc tcacccaagg  
ctgcctccag ccccagcaac ccggccgccc tgcctgtggc ctccgacagc agcccgatgg  
gctccaagac caaggagaca gactcaccca gcacgcctgg caaggaccag cgctccatga  
tccttcggtc acgcaccaaa acccaggaga tcttccactc caagcggcgg aggccctctg  
agggccggct ccccaactgc cgtgccacca agaagctcct cgacaacagc cacttgcccg 
ccacattcaa ggtctccagc agcccccaga aggagggcag ggtgagccag cgggcaaggg  
tccccaaacc tggtgcaggc agcaagctct ctgaccggcc cctccatgcg ctcaaaagga  
agtcggcctt catggcgccg gtccccacca agaagcggaa cctggtcttg cggagccgca  
gcagcagcag cagcaacgcc agtggcaatg ggggagatgg gaaggaggag aggcctgagg  
gttcccccac cctcttcaag aggatgtctt ctcccaagaa agccaagccc accaagggca  
atggcgagcc tgccacaaag ctcccacccc cggagacccc cgatgcctgc ctcaagctcg  
cctctcgggc agccttccag ggggccatga agaccaaggt gctgccaccc cggaagggcc  
ggggcctgaa gctggaagcc atcgtgcaga agatcacctc gcccagcctc aagaagttcg  
catgtaaagc gccaggggcc tctcctggta atcctctgag cccatccctt tccgacaaag SHE515F 
accgtgggct caagggtgct gggggcagcc cagtgggggt ggaagaaggc ctggtaaatg  
tgggcaccgg gcagaagctc ccaacttctg gggctgatcc gttatgcaga aatccaacca  
acagatcctt aaaaggcaaa ctcatgaaca gtaagaaact gtcttctact gactgtttca SHE514R 
aaaccgaggc cttcacatcc ccggaggccc tgcagcctgg ggggactgcc ctggcgccta SHE335 
agaagaggag ccggaaaggc cgggcagggg cccatggac  tctccaaagg cccgctggag  
aagcggccct atcttggccc ggctctgctc ctgactcccc gagacagggc cagtggcaca  
caaggggcca gtgaggacaa ctctggtgga ggaggcaaga agccaaagat ggaggagctg  
ggcctggcct cccagccccc ggagggcagg ccctgccagc cccagacaag ggcacagaaa SNPC4530T 
cagccaggcc acaccaacta cagcagctat tccaagcgga agcgcctcac tcggggccgg  
gccaagaaca ccacctcttc accctgtaag gggcgtgcca agcgacgacg acagcagcag  
gtgctgcccc tggatcccgc agagcctgaa atccgcctca agtacatttc ctcttgcaag  
cggctgaggt cagacagccg gacccccgcc ttctcaccct tcgtgcgggt ggagaagcga  
gacgcgttca ccaccatatg cactgttgtc aactcccctg gagatgcgcc caagccccac  
aggaagcctt cctcctctgc ctcctcttcc tcatcctcgt cctcgttctc cttggatgca  
SHE509F 
SHE510
 
SHE513
 
G3183A 
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gccggggcct ccctggccac actccctgga ggctccatcc tgcagccgcg gccctccttg  
cccctctcct ccacgatgca cttggggcct gtggtttcca aggccctgag tacctcttgc SHE516R 
cttgtttgct gcctctgcca aaacccggcc aacttcaagg accttgggga cctctgtggg  
ccctactacc ctgaacactg cctccccaaa aagaagccaa aactcaagga gaaggtgcgg SHE339 
ccagaaggca cctgtgagga ggcctcgctg ccgcttgaga gaacactcaa aggtcccgag SHE336 
tgtgcagctg ccgccactgc cgggaagccc cccaggcctg acggcccagc tgacccggcc  
aagcagggcc cactgcgcac cagtgcccgg ggcctgtccc ggaggctgca gagctgctac SNP  
tgctgtgatg gccgggagga tgggggcgag gaggcagccc cagccgacaa gggtcgcaaa  
catgagtgca gcaaggaggc tccggcagag cccggcgggg aggcccaggag cactgggtgc G5423A  
atgaggcctg tgccgtgtgg accggcggcg tctacctggt ggccgggaag ctctttgggc  
tgcaggaggc catgaaggtg gccgtggaca tggtaagagg ccagcccagc cagggtgggg end E3 
agtgtggggt tccaaaggac aggcaggcag gcagtcgggg agccccttgt ttctagtgct  
acagtgtggg ccaaatgtgt ctgcagtctc gggacaatct gcagagtcct gagcctctct  
ggggtgtgtg ggggaagtgg aggcacccat ctggctaagg caggtcacac tcacctaccc  
tgtcccagga gacttcccgc cggggcccgt atgcccagcc accgccactc tcccactcac  
ctggcatctt caggctccag ccccacccag aatccactgg gcccctcccc atgctgtcac  
cggagatgcc aaggcccaga gaacacgagg actcccaaga ttgaacatca gggctgcccc  
gggcggtgca agagcaagtt gcccaccctc tgttcctgtc tccattgcct ctgggatgaa  
gctaagggct caggaagacc ctctctggcg acacaggctt ggtgcatgga cccagtcaca  
gggttcctcc ctctgcagga cagtccatgg ggtcacacag tcacaacagg cagggcgggg  
cagatccaga ccctctcacc attggctctg agaccagctt tggaagccat agtcactgag  
 
Exon 4 
 
gagtagctgg gactacaggc acacaccacc aaccctcact attttttgta gagacagttt  
caccatgttg cccaggctgg tatcaaactc ctggactcag gcgatcctcc caccttggcc  
tcccagagtg ctgggattac aggcatgagc cactgcacct ggcctaccag cctgtaaagc  
ttgagggctg ggctccaact ggagactcac ctgcctttcc tttctcttca tcagatgtgt SHE527F 
tccagctgcc aagaagccgg ggccaccatt gggtgctgcc acaaaggatg cctccacacc SNPT5601C 
taccactacc cgtgtgccag cgatgcaggt acgagcccgc ccaggaacag gagggcattg SHE528R 
gagcccatcc aagcagtcca gggggaccct ccctgggcac agctccccaa acccaggccc  
catctcactc ttcagtttcc ctcctctctt gccccagcaa ttcttttatc cttctgtctg  
cctagacctc tgctgggcaa tgccagggac atggaaatga ggcattcccc aggcacctgc  
 
Exon 5 
 
caagacaaga tcacacaggc cagtctctta ggaggcagtg acaagtgtgg ctggcagagt  
aaggcgggag ggagggaggg actgagggac tgcctcaagt gaggaggggc ggcacgtgga  
actcaggggg aaaagctctc cgcggaggag gtgaggtgag tcaagactgc caggccaggg  
gccgcacccg cgccgtggag tggagtggag tgtggagggt tttgtgcaga atctgattaa RA46 
ctctttgaaa agagcccctg cagtctggag cctcgcgggc agtgcggctc ccctcctggc  
tgcagacaaa accccacagc tgtggggccc ccaccctgtc ctaaccaccg aaacttctct  
ttggtcacag gttgcatatt catcgaagag aacttttctt tgaaatgtcc caaacataag E5  
gtaggggacc acagtgtttt gtagggcgag gggtgtcaag cgggagagga gccccacctc RA45 
gcacctcctt cacagtcccc tgggccccct tggctgcgca gccccgcagg gcccagccct  
aggggaggga gctctccccg cccaccccca ggagcccccg ccgccgtcca gctcaggtcc  
ctgtccactt gcgcgccgcc gccgccgaaa acccgcaggc gtcggggcat gggcagccag  
gggctggagg gcgtccctgg gacggcctcc ctgcagctcc ccaagatagg tgacagagtg  
gggcaggcgg gggcgcggga cggtggcacg gagctgaagg cgaaggtgaa ggtgaagctg  
 
Exon 6 and some 3'UTR 
 
gcggagaccc cagccgcgct ctggggtcgc ctgggtctgg ggcttaggcg gggggcccac  
actgggggcg gggcctatgg actgtgaagt ccgaggtcgt cggtaactgg cgggcgggcg SHE345  
tcttttgcag aggctgccgt agtaatccac cccaacggcc ggaggagccg ccggagcccg E6 
cctgcccgcc cgccgccgaa ggagaggagc cgcctgcgca gcccccgggc ctttgagctg UTR  
ctcccagcgc tggtccagag ccgatccttg atccgggtcc cggatcgtgg atccggccgc  
SHE340 
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ctagggctca gacttgcggc cccgggttgg gaggaaaacc cgttccggag ccgcctgctc  
ccggaaccgg acggcacagg gcgttcttgc ccaccccagg ggccaggctt gcggaggggg  
agcccgcgga gcggccagac tccccggggc gctcagcctc cggcgagggt gggagacggc  
tttgtcctgg ggacactttc cctctggaat ctcaagacga cgtggcacac attccacgtg  
ggtgctgccg ccaccccagt cggtcgtggc gtgcagctgg gagccctggg cttgggggtg  
ggggtcgaaa cagtactgga agaggcggag ggcggctcct agctccgtgg actaggcggg  
ggagaaagga agcctttctg agagcgggct aggccggcac tggagaggcc ggagcctttg  
gaacaaaccg tgcggaacgc gtccaggggc cttcccgccc agcctttgcc agatctctcg  
tgcggttcgg gcaaagccgg ggtagacctg ggctatgctc agttaggggt tgcgggatcc UTR 
ccgagtgtgg gcgggactgg gacacccttt ggcctctgtt tgtccccttt ccagtcctcc SHE346 
accccacccc tggagcccag cctgggagcg caaaacccaa gaagcggcca gaacgcacct  
ccggctccgg cggacgcgcg accgttgtgc accaccaggg accgccgcgc ctactctgca  
 
Figure 1: Sequenced Exons from RAI1-The RAI1 gene is represented above and the 
primers used to sequence each fragment are underlined. The sequenced areas are 
highlighted with yellow, green, and pink. There are no further meanings associated with 
the colorings besides red highlight, which signifies overlap between adjacent sequences. 
SNPs are located and highlighted using circles and blue on the particular nucleotide.  
  
 
DNA Sequencing and Alignment Analysis 
Sequence Reaction Primer Normal or Patient DNA Nucleotide Changes 
1 SHE 505 Normal - 
2 SHE 505 Patient SNP G269C, C493A 
4 SHE 506 Patient SNP G269C, C493A, G837A 
5 SHE 508 Normal - 
6 SHE 508 Patient - 
7 SHE 509 Normal - 
8 SHE 509 Patient - 
9 SHE 510 Normal - 
10 SHE 510 Patient - 
11 SHE 514 Normal - 
12 SHE 514 Patient - 
13 SHE 335 Normal - 
14 SHE 335 Patient - 
15 SHE 336 Normal - 
16 SHE 336 Patient - 
17 SHE 339 Normal - 
18 SHE 339 Patient - 
19 SHE 340 Normal - 
20 SHE 340 Patient - 
Table 2: Sequence Alignment Results From ACGT- Twenty of the twenty-six reactions 
sent to ACGT, Inc. had successful sequencing that allowed for alignment against a search 
query on the NCBI website. SNPs were found using PCR reaction 2 for both the forward 
and reverse primers. Two SNPs were found for the forward primer and three SNPs were 
found using the reverse primer. Of the successful sequencing reactions, no other SNPs 
were found in PCR sequences for either the forward or reverse primers. 
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Sequence Reaction Primer Normal or Patient DNA Nucleotide Changes 
1 SHE 507 Normal - 
2 SHE 507 Patient - 
3 SHE 513 Normal - 
4 SHE 513 Patient - 
5 SHE 527 Normal - 
6 SHE 527 Patient SNP T5601C 
Table 3: Sequence Alignment Results From VCU- The six sequencing reactions were 
sent for sequencing at VCU as an initial examination of the sequence alignment. The 
SNP T5601C was found in the SMS 358 patient DNA using the SHE 527 primer.  
 
Modifications to the pivot table 
 
During the alignment of sequences from ACGT, Inc., SNPs were identified in the 
patient DNA in the sequence produced by primer set SHE 505/506. Two SNPs, G269C 
and C493A, were found using the forward primer SHE 505. Using the reverse primer, 
SHE 506, the same SNPs were found as in the forward primer, but an additional SNP was 
found as well – G837A. All three of the SNPs are possible SNPs within the region and 
have been found in other SMS patients. All three of the SNPs are highlighted in Figure 1 
and their location within exon 3 can be visualized. No other SNPs were found in the 
patient or normal DNA when aligned with the query search on the NCBI website.   
The discovered SNPs and corresponding phenotypes for patient SMS 358 were 
added to database and a new pivot table was created. The addition of the SNPs from 
patient SMS 358 added as much as 4 SNPs for a particular phenotype total and in many 
cases, did not change the phenotype total values at all. After the initial pivot table was 
created, the pivot table was then grouped according to the common phenotype groups 
according to Dr. Elsea’s lab. The observed phenotypes that could not be grouped were 
then attached to the same table underneath of the grouped phenotypes. The separation 
between grouped and ungrouped phenotypes is not a matter of separation based on 
importance to the study, but rather just to keep track between the grouped phenotypes and 
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the individual phenotypes observed in the patient population. After reducing the total 
amount of data in the table, the data was better visualized and the most prominent SNPs 
could be identified. The number of patients found with a particular SNP for a given 
phenotype can be observed in Appendix D. The frequency values of the same data can be 
found in Appendix E. Any differences between the original and modified pivot tables as a 
result of the addition of the data from patient SMS 358 were highlighted.  
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Discussion 
 
Through analysis of the frequency of SNPs in the patient population, it was found 
that there were five main SNPs in the patient population. Further analysis of the original 
pivot table found that these five common SNPs were more commonly associated with 
phenotypes found in patients with SMS than other SNPs. The more prominent SNPs 
found in the pivot table were C493A, G1992, G269C, G837A, and T5601C and were 
observed more frequently in patients with given phenotypes associated with SMS. A 
comparison of SNP frequency from the patient analysis to the genral population was 
performed using the SNP information found on the NCBI database. The patients in the 
analysis were all of European decent and were compared to the frequency data of entries 
with European decent for each SNP. Four of the five SNPs found in the patient 
population of this analysis revealed similar frequencies to the SNPs entered into the 
database. However, SNP G1992A was observed 75.5% of the time in the patient analysis 
and according to the information on the NCBI databse has a frequency of 0.017. This is a 
significant finding that could lead to increased interest in this particular SNP. The 
information on the NCBI website is expanded daily and both the current patient analysis 
and the NCBI website need more patient data to strengthen this finding. 
The sequencing reactions performed on patient SMS 358 found all the SNPs 
except for G1992A in the sequenced DNA. The forward primer, SHE 505, identified 
SNPs G269C and C493A. The reverse primer, SHE 506, found SNPs G269C, C493A, 
and G837A when sequencing this fragment of exon 3. The SNP G837A is located closer 
to the end of the fragment than the other two SNPs found in the PCR product and was not 
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found using the forward primer. The last 20 bases were disregarded when using the 
forward primer because this sequencing is unreliable; the SNP G837A was within the last 
20 bases and was not found (Zies, Pers. Comm). However, when the reverse primer was 
used to sequence the same PCR fragment, the SNP was found and added to the database 
for patient SMS 358. The fourth SNP, T5601C, was found in exon 4 of the patient DNA 
using the forward primer SHE 507. The SNPs were matched with the corresponding 
phenotypes of the patient and added to the pivot table.  
 The sequence that was unsuccessful during the PCR reactions involved primers 
SHE 513 and 514. This region of exon 3 included the most frequently observed SNP 
G1992A and it is important that this region be sequenced to enhance the current findings. 
The identification of this SNP in patient SMS 358 would allow the SNP to be added to 
the other four most common SNPs. All five of the most common SNPs could be 
identified and added to the pivot table for this particular patient and their phenotypes—
only strengthening the findings.  
The modified pivot table was grouped and compared to the grouped version of the 
original pivot (not shown). Some of the phenotypes increased the total number of SNPs 
because all four of the SNPs were found in the patient, but in many of the phenotypes, no 
changes were observed. The frequency of SNPs found in patient SMS 358 increased, 
while the frequencies of the other SNPs that were not found decreased. While comparing 
and analyzing the original and modified pivot tables, the values in each of the pivot tables 
only increased slightly due to the addition of SNPs from one patient. It is important to 
realize that this bioinformatic study is a work in progress, but the data found associated 
with patient SMS 358 follows the trend of other members in the original patient 
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population. In order to build a stronger database, patient samples must be added one at a 
time to strengthen the relationships between observed phenotypes and SNPs found within 
the patient population. Strengthening the developed database will allow for a more 
efficient method of detection by identifying the most prevalent SNPs associated with a 
given phenotype. This method may lead to an improved diagnosis for patients with 
phenotypes associated with SMS, but do not have a deletion of DNA in the appropriate 
region of chromosome 17. Detection of abnormalities utilizing SNPs may also help 
individuals with other genetic disorders as well.  
 The sequencing attempted at the University of Mary Washington was 
unsuccessful and possible future adjustments are needed to the protocol so that 
sequencing of these reactions can be done at UMW. The sequencing of these sequences is 
possible because the same PCR products were successfully sequenced when sent away to 
sequencing core facilities. The two variables that could be changed in the sequencing 
reactions were the volumes of the DNA and primers in the reactions. The initial 
concentrations of the PCR products were never determined and arbitrary volumes of each 
the DNA and primers were tried. Adjustments to the DNA and primer concentrations 
could be made until a working combination is found. However, the controls of the 
reactions were unsuccessful as well and additional problems could be present in the 
sequencing process. It was determined that defective Sample Loading Solution (SLS) was 
used in the loading of samples into the plates and thus causing the sequencing to be 
unsuccessful. Despite the use of brand new SLS in the last attempt at sequencing, the 
sequencing failed to produce valid sequence for either the normal or patient DNA. The 
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development of a more reliable, stream-lined approach for ethanol precipitation reactions 
using plates is also needed.  
 The bioinformatic study performed allowed for a higher resolution 
analysis using Single Nucleotide Polymorphisms (SNPs) to ultimately improve the 
detection of non-deletion Smith-Magenis Syndrome cases. The identification of the 
common SNPs and their association with the phenotypes of non-deletion SMS patients 
was evaluated. The study determined the prevalence of particular phenotypes associated 
with specific SNPs and expanded the study by adding a new SMS case to further improve 
the statistics of the study. The findings of the study will contribute to improvements in 
the methods of detection for SMS and increase the understanding of the relationship 
between the observed phenotypes and SNPs seen in SMS. Although more work needs to 
be done to strengthen the findings of this project, I enjoyed doing research that could 
enhance the detection of Smith-Magenis Syndrome in the future.    
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Appendix A – Abbreviations and Full Names of Phenotypes
 
Abbreviation Full Phenotype 
SI Self -injury 
AbnEar Abnormal ear shape 
AbnEye Eye abnormalit ies 
AbnGait Abnormal gait  
ADD At t ent ion Def icit  Disorder 
AidScho Has an aide at  school 
App Problems wit h appet it e/ eat ing 
AskRef Ask for and refuse object s 
Awake Awaken during t he night  
BdFc Broad face 
Bedwet Bed wet t ing 
BMI Body Mass Index  
BowObs Bowel obst ruct ion 
Brceph Brachycephaly 
BrNs Broad Nasal bridge 
BrProb Breat hing problems 
ChApp Change in appet it e 
CL Clef t  lip 
CoHand Cold hands/ feet  
Const Regular const ipat ion 
CP Clef t  palat e 
Crawl Crawl 
DecDTR Decreased t endon ref lexes 
DecrEx 
Decreased t olerance for 
exercise 
DecSen Decreased sensit ivit y t o pain 
DelTT Delayed t oilet  t raining 
DenAbn Dent al abnormalit ies 
Diab Diabet es 
Diar Regular loose bowel movement  
DifBed Dif f icult  t o put  t o bed 
DifDig Dif f icult y digest ing foods 
DifShoe Dif f icult y f inding shoes t hat  f it  
DifSwa Dif f icult y swallowing 
Difwake Dif f icult y waking in morning 
Dlips Down-t urned upper lip 
DrySkin Dry skin or psoriasis 
EarInf Frequent  ear infect ions 
ElLim Elbow limit at ions 
Esot Esot ropia 
ExcChok Excessive choking 
ExcDrool Excessive drooling 
Exot Exot ropia 
FavFood Favorit e food 
FdNotEat Food will absolut ely not  eat  
  
Abbreviation Full Phenotype 
FeedPro 
Feeding problems during 
infancy 
FHxNTD 
Family member wit h a neural 
t ube defect  
Folic 
Folic acid or prenat al vit amins 
t aken 
FrBoss Front al Bossing 
FruCom 
Frust rat ion change 
w/ communicat ion 
GER GER (gast roesophageal ref lux)  
Glasses Wear glasses 
HamToe Hammer t oes 
HandBite Hand Bit ing 
HdBang Head banging 
Heart Congenit al heart  defect s  
HighChol High cholest erol 
HL Hearing impairment  
HLFood 
Precaut ions t o hide or lock 
food 
Hoarse Hoarse voice 
Hyper Hyperact ivit y 
Hypo Hypot onia 
IQ Int elligence Quot ient  
IrisAbn Iris abnormalit ies 
KidAbn Kidney abnormalit y 
Laear Lowset / Angulat ed ears 
Laugh Laugh 
LUHand 
Abnormally lit t le use of  t he 
hands 
MacDeg Macular degenerat ion 
Mcornea Microcornea 
MidHypo Midface hypoplasia 
MusCram Muscle cramping 
MusWeak Muscle weakness 
Myopia Myopia 
NapDay Naps during t he day 
NapProb 
Same problems napping as at  
night  
NmlApp Normal appet it e (1st  year)  
NmlIQ Normal IQ  
NpWoBd Naps w/ o being put  t o bed 
NTD Neural t ube defect   
Nyst Nyst agmus 
Obese Obesit y 
OCD Obsessive compulsive behavior 
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Onchy 
At t empt ed pulling of f  
f ingernails 
OverW Overweight  
Pcav Pes cavus 
PckSkin Pick at  skin 
PerNeu Peripheral neuropat hy 
Abbreviation Full Phenotype 
PETube Tubes insert ed 
Polyembo St ick t hings in orif ices 
Pplan Pes planus 
Prog Prognat hism 
PrRegFo Problem regulat ing food int ake 
R/Sinf Respirat ory/ Sinus infect ions 
RctCross 
React ion t o ppl wit h crossed 
arms/ legs 
RetDet Ret inal det achment  
Rollover Roll over 
RtBed Rout ine bedt ime 
Rtwaking Rout ine waking t ime 
School At t ends school 
Scol Scoliosis 
Seiz Seizures 
SelfHug Self  hugging 
Sent Complet e sent ences 
ShHand Short  broad hands 
Short Short  st at ure 
SignLan Uses sign language 
Situp Sit  up wit hout  aid 
SkVeAbn Skelet al/ vert ebral changes 
Sleep  Sleep dist urbance 
SlMed Takes sleep medicat ions 
SlWlk Sleep walking 
  Abbreviation Full Phenotype 
Smile Smile 
Speak Spoken words 
SpScho 
At t ends special school or 
program 
SrchFood Searching for food at  night  
Stand Pull t o st anding 
Stdonown St and wit hout  aid 
Step St eps/ cruise 
Stereo St ereot yping 
Strab St rabismus 
SwalProb Swallowing problems 
Syn Synophrys 
TbNap Trouble napping 
TonPap Tongue papillae 
Tremor Tremors 
Tsyn Syndact yly (2-3 t oe)  
Twirl Tendency t o t wirl object s 
Twoword Speak 2 work sent ences 
Upeye Upslant ing eyes 
UriRefl urinary ref lux 
UTI Frequent  Urinary t ract  infect ion 
VPI 
Velo-pharyngeal-insuf f iciency 
and hypot onia relat ed issues 
Walk Walk/ st eps wit hout  assist ance 
Wander Wandering at  night  
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Appendix B – Pivot Table – Number of SNPs 
Phenotype A
36
34
G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
To
ta
l 
AbnEar 1 1 1 0 7 0 13 7 1 1 0 10 14 56 
AbnEye 0 1 2 0 11 0 15 12 1 0 1 10 15 68 
AbnGait 1 1 1 0 6 0 10 6 0 0 1 6 11 43 
ADD 1 1 0 0 3 0 6 3 0 1 1 4 7 27 
AidScho 0 1 1 0 5 0 8 5 0 0 1 4 10 35 
App 1 1 1 0 6 0 8 6 0 1 0 7 7 38 
AskRef 1 0 1 0 3 0 5 3 0 0 1 3 5 22 
Awake 1 1 0 0 13 0 20 13 0 1 1 13 24 87 
BdFc 1 0 4 0 15 0 18 15 1 0 0 14 17 85 
Bedwet 1 0 1 0 7 0 7 7 0 0 0 5 6 34 
Brceph 0 1 1 0 12 0 16 13 1 0 1 11 17 73 
BrNs 0 1 2 1 12 0 20 11 1 0 0 13 18 79 
BrProb 1 1 0 0 2 0 2 2 0 0 0 3 5 16 
ChApp 1 1 0 0 4 0 6 4 0 1 0 5 8 30 
CL 0 1 0 0 0 0 2 0 0 0 0 1 3 7 
CoHand 1 1 0 0 2 0 3 2 0 0 0 3 5 17 
Const 1 0 0 0 5 0 8 5 1 0 1 4 8 33 
CP 0 1 0 0 0 0 2 0 0 0 0 1 3 7 
Dakno 1 0 0 0 1 0 5 1 0 1 1 2 5 17 
DecrEx 0 1 1 0 1 0 4 1 0 0 1 2 3 14 
DecSen 1 1 2 0 11 0 17 11 1 1 1 13 15 74 
DelTT 0 1 0 0 3 0 6 3 0 0 0 2 8 23 
DenAbn 0 1 1 0 3 0 4 3 0 0 0 3 5 20 
Diab 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
Diar 0 1 0 0 1 0 3 1 0 0 1 2 4 13 
DifBed 1 1 0 0 4 0 6 4 0 1 1 5 7 30 
DifDig 0 0 0 0 2 0 4 2 0 0 1 2 3 14 
DifShoe 1 0 1 0 3 0 4 3 0 0 1 3 4 20 
DifSwa 1 1 0 0 2 0 4 2 0 0 0 2 4 16 
Difwake 1 0 0 0 2 0 3 2 0 1 0 3 2 14 
Dlips 1 1 3 0 16 1 20 16 1 0 0 14 19 92 
DrySkin 1 0 0 0 6 0 8 6 0 1 1 5 10 38 
EarInf 1 0 2 0 15 0 12 14 0 0 0 11 13 68 
ElLim 0 1 0 0 1 0 2 1 0 0 0 1 4 10 
Esot 0 0 0 0 1 0 5 1 0 0 1 0 4 12 
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Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
To
ta
l 
ExcChok 1 1 0 0 3 0 4 3 0 0 0 4 5 21 
ExcDrool 0 1 0 0 1 0 4 1 0 0 0 2 6 15 
Exot 0 1 1 0 2 0 3 2 0 0 0 3 3 15 
FavFood 1 0 0 0 4 0 6 4 0 0 0 3 6 24 
FdNotEat 1 0 0 0 3 0 7 3 0 1 1 4 8 28 
FeedPro 0 1 1 0 8 0 11 8 1 0 0 8 11 49 
Folic 0 0 1 0 2 0 6 2 0 0 1 2 4 18 
FrBoss 1 1 3 0 11 0 21 12 1 0 1 13 16 80 
FruCom 1 0 0 0 4 0 7 4 0 1 1 5 8 31 
GER 0 0 0 0 1 0 1 1 1 0 0 1 2 7 
Glasses 0 1 2 0 4 0 6 4 0 1 0 6 5 29 
HandBite 1 0 0 0 11 0 14 11 0 0 0 8 12 57 
HdBang 1 1 1 0 9 0 18 10 0 1 1 9 19 70 
Heart 0 1 1 0 3 1 5 3 0 0 0 4 5 23 
HighChol 0 1 0 0 4 0 6 4 0 0 1 3 8 27 
HL 1 0 2 0 8 0 7 8 1 0 0 7 8 42 
HLFood 1 0 1 0 6 0 8 6 0 1 0 6 7 36 
Hoarse 1 1 1 0 11 1 13 11 0 0 1 12 15 67 
Hyper 1 1 0 0 5 1 9 6 0 1 1 6 10 41 
Hypo 1 1 2 0 14 0 17 14 1 0 0 10 16 76 
KidAbn 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
Laear 0 0 0 0 4 0 8 3 1 1 0 6 6 29 
LUHand 0 0 0 0 0 0 1 0 0 0 0 0 2 3 
MidHypo 1 1 2 1 13 1 22 13 1 0 1 12 23 91 
MusCram 0 0 0 0 0 0 1 0 0 0 1 0 1 3 
MusWeak 0 1 1 0 1 0 4 1 0 0 0 2 3 13 
Myopia 0 1 2 0 4 0 7 5 0 0 1 4 10 34 
NapDay 1 1 0 0 5 0 9 5 0 0 1 3 9 34 
NmlApp 1 0 0 0 4 0 8 4 0 1 1 5 9 33 
NmlIQ 0 0 0 0 1 0 1 1 0 0 0 1 1 5 
NpWoBd 1 1 0 0 2 0 6 2 0 0 1 2 7 22 
NTD 0 0 0 0 1 0 1 1 0 0 0 0 1 4 
Obese 0 0 2 0 4 0 4 4 0 0 0 3 1 18 
OCD 1 1 1 0 4 0 9 4 0 1 1 7 9 38 
Onchy 0 0 0 0 9 0 11 9 0 0 0 10 12 51 
OverW 0 0 2 2 9 0 13 9 0 0 0 8 11 54 
Pcav 0 0 0 0 0 0 1 0 0 0 0 0 1 2 
PckSkin 1 1 0 1 9 0 15 9 0 1 1 8 16 62 
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Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
To
ta
l 
Peripheral neuropathy 1 1 1 0 7 0 12 7 1 0 1 8 11 50 
PETube 1 0 0 0 7 0 7 7 0 0 0 7 9 38 
Polyembo 1 1 1 0 8 0 13 9 0 0 1 10 15 59 
Pplan 0 1 1 0 5 0 7 5 0 0 1 5 7 32 
Prog 0 1 0 0 5 0 7 5 0 0 1 6 10 35 
PrRegFo 1 0 1 1 4 0 9 4 0 1 1 5 7 34 
R/Sinf 0 0 0 0 1 0 1 1 0 0 0 1 1 5 
RctCross 0 0 0 0 1 0 3 1 0 0 1 1 3 10 
RtBed 1 1 1 0 5 0 9 5 0 1 1 6 10 40 
Rtwaking 1 0 0 0 4 0 8 4 0 1 1 5 9 33 
School 1 1 1 0 6 0 11 6 0 1 1 6 12 46 
Scol 0 1 0 0 3 0 4 3 0 0 0 3 7 21 
Seiz 1 0 1 1 7 0 9 7 0 0 0 5 10 41 
SelfHug 0 0 0 0 11 0 15 11 0 1 1 9 17 65 
Sex 0 0 2 1 11 0 16 12 1 1 1 10 17 72 
ShHand 0 1 1 0 7 1 10 6 1 0 1 7 12 47 
Short 0 1 1 0 4 1 8 4 0 0 1 3 10 33 
SI 1 1 2 1 17 0 27 17 0 1 1 16 28 112 
SignLan 1 0 0 0 3 0 5 3 0 0 0 2 6 20 
Situp 0 0 0 0 0 0 2 0 0 0 0 1 1 4 
SkVeAbn 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
Sleep disturbance 1 1 2 0 16 0 23 16 0 1 1 16 26 103 
SlMed 1 0 1 0 6 0 7 6 0 0 1 6 5 33 
Speak 0 0 1 0 3 0 4 3 0 0 0 2 3 16 
SpScho 1 1 1 0 6 0 10 6 0 1 1 6 12 45 
SrchFood 0 0 0 0 1 0 0 1 0 0 0 1 1 4 
Stand 0 0 0 0 1 0 1 1 0 0 0 1 1 5 
Stdonown 0 0 0 0 0 0 1 0 0 1 0 1 1 4 
Step 0 0 0 0 0 0 1 0 0 0 1 0 1 3 
Stereo 1 1 2 0 15 0 22 15 0 0 1 13 20 90 
Strab 1 1 1 0 11 0 14 12 1 0 1 10 14 66 
SwalProb 0 1 0 0 0 0 2 0 0 0 0 1 3 7 
Syn 0 1 3 0 8 0 13 9 0 0 0 7 15 56 
Tremor 1 0 0 0 2 0 4 2 0 1 0 2 3 15 
Tsyn 0 0 1 0 2 0 2 2 0 0 0 1 1 9 
Twirl 0 0 0 0 2 0 5 2 0 1 1 2 5 18 
Upeye 1 0 1 0 7 0 10 7 0 0 0 6 9 41 
UriRefl 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
34 
 
 
 
 
 
Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
To
ta
l 
UTI 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
VPI 1 1 0 0 4 0 7 4 1 0 0 5 9 32 
Wander 1 0 0 0 2 0 3 2 0 1 0 3 4 16 
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Appendix C- Pivot Table – Frequency of SNPs 
 
Phenotype A
36
34
G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
AbnEar 1.8 1.8 1.8 0.0 12.5 0.0 23.2 12.5 1.8 1.8 0.0 17.9 25.0 
AbnEye 0.0 1.5 2.9 0.0 16.2 0.0 22.1 17.6 1.5 0.0 1.5 14.7 22.1 
AbnGait 2.3 2.3 2.3 0.0 14.0 0.0 23.3 14.0 0.0 0.0 2.3 14.0 25.6 
ADD 3.7 3.7 0.0 0.0 11.1 0.0 22.2 11.1 0.0 3.7 3.7 14.8 25.9 
AidScho 0.0 2.9 2.9 0.0 14.3 0.0 22.9 14.3 0.0 0.0 2.9 11.4 28.6 
App 2.6 2.6 2.6 0.0 15.8 0.0 21.1 15.8 0.0 2.6 0.0 18.4 18.4 
AskRef 4.5 0.0 4.5 0.0 13.6 0.0 22.7 13.6 0.0 0.0 4.5 13.6 22.7 
Awake 1.1 1.1 0.0 0.0 14.9 0.0 23.0 14.9 0.0 1.1 1.1 14.9 27.6 
BdFc 1.2 0.0 4.7 0.0 17.6 0.0 21.2 17.6 1.2 0.0 0.0 16.5 20.0 
Bedwet 2.9 0.0 2.9 0.0 20.6 0.0 20.6 20.6 0.0 0.0 0.0 14.7 17.6 
Brceph 0.0 1.4 1.4 0.0 16.4 0.0 21.9 17.8 1.4 0.0 1.4 15.1 23.3 
BrNs 0.0 1.3 2.5 1.3 15.2 0.0 25.3 13.9 1.3 0.0 0.0 16.5 22.8 
BrProb 6.3 6.3 0.0 0.0 12.5 0.0 12.5 12.5 0.0 0.0 0.0 18.8 31.3 
ChApp 3.3 3.3 0.0 0.0 13.3 0.0 20.0 13.3 0.0 3.3 0.0 16.7 26.7 
CL 0.0 14.3 0.0 0.0 0.0 0.0 28.6 0.0 0.0 0.0 0.0 14.3 42.9 
CoHand 5.9 5.9 0.0 0.0 11.8 0.0 17.6 11.8 0.0 0.0 0.0 17.6 29.4 
Const 3.0 0.0 0.0 0.0 15.2 0.0 24.2 15.2 3.0 0.0 3.0 12.1 24.2 
CP 0.0 14.3 0.0 0.0 0.0 0.0 28.6 0.0 0.0 0.0 0.0 14.3 42.9 
Dakno 5.9 0.0 0.0 0.0 5.9 0.0 29.4 5.9 0.0 5.9 5.9 11.8 29.4 
DecrEx 0.0 7.1 7.1 0.0 7.1 0.0 28.6 7.1 0.0 0.0 7.1 14.3 21.4 
DecSen 1.4 1.4 2.7 0.0 14.9 0.0 23.0 14.9 1.4 1.4 1.4 17.6 20.3 
DelTT 0.0 4.3 0.0 0.0 13.0 0.0 26.1 13.0 0.0 0.0 0.0 8.7 34.8 
DenAbn 0.0 5.0 5.0 0.0 15.0 0.0 20.0 15.0 0.0 0.0 0.0 15.0 25.0 
Diab 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
Diar 0.0 7.7 0.0 0.0 7.7 0.0 23.1 7.7 0.0 0.0 7.7 15.4 30.8 
DifBed 3.3 3.3 0.0 0.0 13.3 0.0 20.0 13.3 0.0 3.3 3.3 16.7 23.3 
DifDig 0.0 0.0 0.0 0.0 14.3 0.0 28.6 14.3 0.0 0.0 7.1 14.3 21.4 
DifShoe 5.0 0.0 5.0 0.0 15.0 0.0 20.0 15.0 0.0 0.0 5.0 15.0 20.0 
DifSwa 6.3 6.3 0.0 0.0 12.5 0.0 25.0 12.5 0.0 0.0 0.0 12.5 25.0 
Difwake 7.1 0.0 0.0 0.0 14.3 0.0 21.4 14.3 0.0 7.1 0.0 21.4 14.3 
Dlips 1.1 1.1 3.3 0.0 17.4 1.1 21.7 17.4 1.1 0.0 0.0 15.2 20.7 
DrySkin 2.6 0.0 0.0 0.0 15.8 0.0 21.1 15.8 0.0 2.6 2.6 13.2 26.3 
EarInf 1.5 0.0 2.9 0.0 22.1 0.0 17.6 20.6 0.0 0.0 0.0 16.2 19.1 
ElLim 0.0 10.0 0.0 0.0 10.0 0.0 20.0 10.0 0.0 0.0 0.0 10.0 40.0 
Esot 0.0 0.0 0.0 0.0 8.3 0.0 41.7 8.3 0.0 0.0 8.3 0.0 33.3 
ExcChok 4.8 4.8 0.0 0.0 14.3 0.0 19.0 14.3 0.0 0.0 0.0 19.0 23.8 
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Phenotype A
36
34
G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
T5
60
1C
 
ExcDrool 0.0 6.7 0.0 0.0 6.7 0.0 26.7 6.7 0.0 0.0 0.0 13.3 40.0 
Exot 0.0 6.7 6.7 0.0 13.3 0.0 20.0 13.3 0.0 0.0 0.0 20.0 20.0 
FavFood 4.2 0.0 0.0 0.0 16.7 0.0 25.0 16.7 0.0 0.0 0.0 12.5 25.0 
FdNotEat 3.6 0.0 0.0 0.0 10.7 0.0 25.0 10.7 0.0 3.6 3.6 14.3 28.6 
FeedPro 0.0 2.0 2.0 0.0 16.3 0.0 22.4 16.3 2.0 0.0 0.0 16.3 22.4 
Folic 0.0 0.0 5.6 0.0 11.1 0.0 33.3 11.1 0.0 0.0 5.6 11.1 22.2 
FrBoss 1.3 1.3 3.8 0.0 13.8 0.0 26.3 15.0 1.3 0.0 1.3 16.3 20.0 
FruCom 3.2 0.0 0.0 0.0 12.9 0.0 22.6 12.9 0.0 3.2 3.2 16.1 25.8 
GER 0.0 0.0 0.0 0.0 14.3 0.0 14.3 14.3 14.3 0.0 0.0 14.3 28.6 
Glasses 0.0 3.4 6.9 0.0 13.8 0.0 20.7 13.8 0.0 3.4 0.0 20.7 17.2 
HandBite 1.8 0.0 0.0 0.0 19.3 0.0 24.6 19.3 0.0 0.0 0.0 14.0 21.1 
HdBang 1.4 1.4 1.4 0.0 12.9 0.0 25.7 14.3 0.0 1.4 1.4 12.9 27.1 
Heart 0.0 4.3 4.3 0.0 13.0 4.3 21.7 13.0 0.0 0.0 0.0 17.4 21.7 
HighChol 0.0 3.7 0.0 0.0 14.8 0.0 22.2 14.8 0.0 0.0 3.7 11.1 29.6 
HL 2.4 0.0 4.8 0.0 19.0 0.0 16.7 19.0 2.4 0.0 0.0 16.7 19.0 
HLFood 2.8 0.0 2.8 0.0 16.7 0.0 22.2 16.7 0.0 2.8 0.0 16.7 19.4 
Hoarse 1.5 1.5 1.5 0.0 16.4 1.5 19.4 16.4 0.0 0.0 1.5 17.9 22.4 
Hyper 2.4 2.4 0.0 0.0 12.2 2.4 22.0 14.6 0.0 2.4 2.4 14.6 24.4 
Hypo 1.3 1.3 2.6 0.0 18.4 0.0 22.4 18.4 1.3 0.0 0.0 13.2 21.1 
KidAbn 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
Laear 0.0 0.0 0.0 0.0 13.8 0.0 27.6 10.3 3.4 3.4 0.0 20.7 20.7 
LUHand 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 0.0 0.0 66.7 
MidHypo 1.1 1.1 2.2 1.1 14.3 1.1 24.2 14.3 1.1 0.0 1.1 13.2 25.3 
MusCram 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 33.3 0.0 33.3 
MusWeak 0.0 7.7 7.7 0.0 7.7 0.0 30.8 7.7 0.0 0.0 0.0 15.4 23.1 
Myopia 0.0 2.9 5.9 0.0 11.8 0.0 20.6 14.7 0.0 0.0 2.9 11.8 29.4 
NapDay 2.9 2.9 0.0 0.0 14.7 0.0 26.5 14.7 0.0 0.0 2.9 8.8 26.5 
NmlApp 3.0 0.0 0.0 0.0 12.1 0.0 24.2 12.1 0.0 3.0 3.0 15.2 27.3 
NmlIQ 0.0 0.0 0.0 0.0 20.0 0.0 20.0 20.0 0.0 0.0 0.0 20.0 20.0 
NpWoBd 4.5 4.5 0.0 0.0 9.1 0.0 27.3 9.1 0.0 0.0 4.5 9.1 31.8 
NTD 0.0 0.0 0.0 0.0 25.0 0.0 25.0 25.0 0.0 0.0 0.0 0.0 25.0 
Obese 0.0 0.0 11.1 0.0 22.2 0.0 22.2 22.2 0.0 0.0 0.0 16.7 5.6 
OCD 2.6 2.6 2.6 0.0 10.5 0.0 23.7 10.5 0.0 2.6 2.6 18.4 23.7 
Onchy 0.0 0.0 0.0 0.0 17.6 0.0 21.6 17.6 0.0 0.0 0.0 19.6 23.5 
OverW 0.0 0.0 3.7 3.7 16.7 0.0 24.1 16.7 0.0 0.0 0.0 14.8 20.4 
Pcav 0.0 0.0 3.7 3.7 16.7 0.0 24.1 16.7 0.0 0.0 0.0 14.8 20.4 
PckSkin 1.6 0.0 0.0 0.0 0.0 0.0 50.0 0.0 0.0 0.0 0.0 0.0 50.0 
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Phenotype A
36
34
G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G1
86
7A
 
G1
99
2A
 
G2
69
C 
G3
18
3A
 
G4
51
2T
 
G5
42
3A
 
G8
37
A 
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60
1C
 
Peripheral neuropathy 2.0 1.6 0.0 1.6 14.5 0.0 24.2 14.5 0.0 1.6 1.6 12.9 25.8 
PETube 2.6 2.0 2.0 0.0 14.0 0.0 24.0 14.0 2.0 0.0 2.0 16.0 22.0 
Polyembo 1.7 0.0 0.0 0.0 18.4 0.0 18.4 18.4 0.0 0.0 0.0 18.4 23.7 
Pplan 1.7 1.7 1.7 0.0 13.6 0.0 22.0 15.3 0.0 0.0 1.7 16.9 25.4 
Prog 0.0 3.1 3.1 0.0 15.6 0.0 21.9 15.6 0.0 0.0 3.1 15.6 21.9 
PrRegFo 0.0 2.9 0.0 0.0 14.3 0.0 20.0 14.3 0.0 0.0 2.9 17.1 28.6 
R/Sinf 2.9 0.0 2.9 2.9 11.8 0.0 26.5 11.8 0.0 2.9 2.9 14.7 20.6 
RctCross 0.0 0.0 0.0 0.0 20.0 0.0 20.0 20.0 0.0 0.0 0.0 20.0 20.0 
RtBed 0.0 0.0 0.0 0.0 10.0 0.0 30.0 10.0 0.0 0.0 10.0 10.0 30.0 
Rtwaking 2.5 2.5 2.5 0.0 12.5 0.0 22.5 12.5 0.0 2.5 2.5 15.0 25.0 
School 3.0 0.0 0.0 0.0 12.1 0.0 24.2 12.1 0.0 3.0 3.0 15.2 27.3 
Scol 2.2 2.2 2.2 0.0 13.0 0.0 23.9 13.0 0.0 2.2 2.2 13.0 26.1 
Seiz 0.0 4.8 0.0 0.0 14.3 0.0 19.0 14.3 0.0 0.0 0.0 14.3 33.3 
SelfHug 2.4 0.0 2.4 2.4 17.1 0.0 22.0 17.1 0.0 0.0 0.0 12.2 24.4 
Sex 0.0 0.0 0.0 0.0 16.9 0.0 23.1 16.9 0.0 1.5 1.5 13.8 26.2 
ShHand 0.0 0.0 2.8 1.4 15.3 0.0 22.2 16.7 1.4 1.4 1.4 13.9 23.6 
Short 0.0 2.1 2.1 0.0 14.9 2.1 21.3 12.8 2.1 0.0 2.1 14.9 25.5 
SI 0.0 3.0 3.0 0.0 12.1 3.0 24.2 12.1 0.0 0.0 3.0 9.1 30.3 
SignLan 0.9 0.9 1.8 0.9 15.2 0.0 24.1 15.2 0.0 0.9 0.9 14.3 25.0 
Situp 5.0 0.0 0.0 0.0 15.0 0.0 25.0 15.0 0.0 0.0 0.0 10.0 30.0 
SkVeAbn 0.0 0.0 0.0 0.0 0.0 0.0 50.0 0.0 0.0 0.0 0.0 25.0 25.0 
Sleep disturbance 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
SlMed 1.0 1.0 1.9 0.0 15.5 0.0 22.3 15.5 0.0 1.0 1.0 15.5 25.2 
Speak 3.0 0.0 3.0 0.0 18.2 0.0 21.2 18.2 0.0 0.0 3.0 18.2 15.2 
SpScho 0.0 0.0 6.3 0.0 18.8 0.0 25.0 18.8 0.0 0.0 0.0 12.5 18.8 
SrchFood 2.2 2.2 2.2 0.0 13.3 0.0 22.2 13.3 0.0 2.2 2.2 13.3 26.7 
Stand 0.0 0.0 0.0 0.0 25.0 0.0 0.0 25.0 0.0 0.0 0.0 25.0 25.0 
Stdonown 0.0 0.0 0.0 0.0 20.0 0.0 20.0 20.0 0.0 0.0 0.0 20.0 20.0 
Step 0.0 0.0 0.0 0.0 0.0 0.0 25.0 0.0 0.0 25.0 0.0 25.0 25.0 
Stereo 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 33.3 0.0 33.3 
Strab 1.1 1.1 2.2 0.0 16.7 0.0 24.4 16.7 0.0 0.0 1.1 14.4 22.2 
SwalProb 1.5 1.5 1.5 0.0 16.7 0.0 21.2 18.2 1.5 0.0 1.5 15.2 21.2 
Syn 0.0 14.3 0.0 0.0 0.0 0.0 28.6 0.0 0.0 0.0 0.0 14.3 42.9 
Tremor 0.0 1.8 5.4 0.0 14.3 0.0 23.2 16.1 0.0 0.0 0.0 12.5 26.8 
Tsyn 6.7 0.0 0.0 0.0 13.3 0.0 26.7 13.3 0.0 6.7 0.0 13.3 20.0 
Twirl 0.0 0.0 11.1 0.0 22.2 0.0 22.2 22.2 0.0 0.0 0.0 11.1 11.1 
Upeye 0.0 0.0 0.0 0.0 11.1 0.0 27.8 11.1 0.0 5.6 5.6 11.1 27.8 
UriRefl 2.4 0.0 2.4 0.0 17.1 0.0 24.4 17.1 0.0 0.0 0.0 14.6 22.0 
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UTI 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
VPI 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
Wander 3.1 3.1 0.0 0.0 12.5 0.0 21.9 12.5 3.1 0.0 0.0 15.6 28.1 
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Appendix D –Enhanced Pivot Table – Number of SNPS 
 
Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G
18
67
A 
G
19
92
A 
G
26
9C
 
G
31
83
A 
G
45
12
T 
G
54
23
A 
G
83
7A
 
T5
60
1C
 
To
ta
l 
Self-Injury 1 1 2 1 18 0 27 18 0 1 1 17 29 116 
Sleep Disturbance 1 1 2 0 17 0 23 17 0 1 1 17 27 107 
Hyperactivity 1 1 0 0 5 1 9 6 0 1 1 6 10 41 
Signs of Peripheral Neuropathy 1 1 2 0 11 0 17 11 1 1 1 13 15 74 
Seizure 1 0 1 1 7 0 9 7 0 1 0 5 10 42 
Self-Hug 1 1 2 0 15 0 22 15 0 1 1 13 20 91 
Hypotnia 1 1 2 0 14 0 17 14 1 0 0 10 16 76 
Craniofacial Abnormalities 1 1 4 1 16 1 22 16 1 0 1 15 23 102 
Eye Abnormalities 1 1 2 0 11 0 15 12 1 1 1 10 15 70 
Ear Abnormalities 1 1 1 0 8 0 13 8 1 1 0 11 15 60 
Ear Infections 1 0 2 0 15 0 12 14 0 0 0 11 13 68 
Hearing Loss 1 0 2 0 8 0 7 8 1 0 0 7 8 42 
Oral/Motor Dysfunction 1 1 1 0 9 0 11 9 1 0 0 9 12 54 
Cleft Lip/Palate  0 1 0 0 0 0 2 0 0 0 0 1 3 7 
Dental Anomalies 0 1 1 0 3 0 4 3 0 0 0 3 5 20 
Hoarse Voice 1 1 1 0 12 1 13 12 0 0 1 13 16 71 
Hypercholestorlemia 0 1 0 0 4 0 6 4 0 0 1 3 8 27 
Digestive Problems 1 1 0 0 6 0 8 6 1 0 1 5 9 38 
Overweight 0 0 2 2 9 0 13 9 0 0 0 8 11 54 
Short Stature 0 1 1 0 4 1 8 4 0 0 1 3 10 33 
Scoliosis 0 1 0 0 3 0 4 3 0 0 0 3 7 21 
Heart Defect 0 1 1 0 3 1 5 3 0 0 0 4 5 23 
Kidney Abnormality 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
Breathing Problem 1 1 0 0 2 0 2 2 0 0 0 3 5 16 
AbnGait 1 1 1 0 6 0 10 6 0 0 1 6 11 43 
AidScho 0 1 1 0 5 0 8 5 0 0 1 4 10 35 
App 1 1 1 0 7 0 8 7 0 1 0 8 8 42 
AskRef 1 0 1 0 3 0 5 3 0 0 1 3 5 22 
Bedwet 1 0 1 0 7 0 7 7 0 0 0 5 6 34 
ChApp 1 1 0 0 4 0 6 4 0 1 0 5 8 30 
CoHand 1 1 0 0 2 0 3 2 0 0 0 3 5 17 
DecrEx 0 1 1 0 1 0 4 1 0 0 1 2 3 14 
DelTT 0 1 0 0 3 0 6 3 0 0 0 2 8 23 
Diab 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
DifShoe 1 0 1 0 3 0 4 3 0 0 1 3 4 20 
40 
 
 
 
 
 
Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G
18
67
A 
G
19
92
A 
G
26
9C
 
G
31
83
A 
G
45
12
T 
G
54
23
A 
G
83
7A
 
T5
60
1C
 
To
ta
l 
DrySkin 1 0 0 0 6 0 8 6 0 1 1 5 10 38 
ElLim 0 1 0 0 1 0 2 1 0 0 0 1 4 10 
FavFood 1 0 0 0 4 0 6 4 0 0 0 3 6 24 
FdNotEat 1 0 0 0 3 0 7 3 0 1 1 4 8 28 
Folic 0 0 1 0 2 0 6 2 0 0 1 2 4 18 
FruCom 1 0 0 0 4 0 7 4 0 1 1 5 8 31 
HLFood 1 0 1 0 6 0 8 6 0 1 0 6 7 36 
LUHand 0 0 0 0 0 0 1 0 0 0 0 0 2 3 
MusCram 0 0 0 0 0 0 1 0 0 0 1 0 1 3 
MusWeak 0 1 1 0 1 0 4 1 0 0 0 2 3 13 
NmlApp 1 0 0 0 4 0 8 4 0 1 1 5 9 33 
NmlIQ 0 0 0 0 1 0 1 1 0 0 0 1 1 5 
NTD 0 0 0 0 1 0 1 1 0 0 0 0 1 4 
OCD 1 1 1 0 4 0 9 4 0 1 1 7 9 38 
Pplan 0 1 1 0 5 0 7 5 0 0 1 5 7 32 
Prog 0 1 0 0 6 0 7 6 0 0 1 7 11 39 
PrRegFo 1 0 1 1 4 0 9 4 0 1 1 5 7 34 
School 1 1 1 0 6 0 11 6 0 1 1 6 12 46 
ShHand 0 1 1 0 7 1 10 6 1 0 1 7 12 47 
SignLan 1 0 0 0 3 0 5 3 0 0 0 2 6 20 
Situp 0 0 0 0 0 0 2 0 0 0 0 1 1 4 
SkVeAbn 0 1 0 0 0 0 1 0 0 0 0 1 2 5 
Speak 0 0 1 0 3 0 4 3 0 0 0 2 3 16 
SpScho 1 1 1 0 7 0 10 7 0 1 1 7 13 49 
Stand 0 0 0 0 1 0 1 1 0 0 0 1 1 5 
Stdonown 0 0 0 0 0 0 1 0 0 1 0 1 1 4 
Step 0 0 0 0 0 0 1 0 0 0 1 0 1 3 
Syn 0 1 3 0 8 0 13 9 0 0 0 7 15 56 
Tsyn 0 0 1 0 2 0 2 2 0 0 0 1 1 9 
 
  
41 
 
Appendix E-Enhanced Pivot Table- Frequency of SNPs 
 
Phenotype 
A3
63
4G
 
A4
68
5G
 
A5
17
8T
 
C4
53
0T
 
C4
93
A 
G
18
67
A 
G
19
92
A 
G
26
9C
 
G
31
83
A 
G
45
12
T 
G
54
23
A 
G
83
7A
 
T5
60
1C
 
Self-Injury 0.9 0.9 1.7 0.9 15.5 0.0 23.3 15.5 0.0 0.9 0.9 14.7 25.0 
Sleep Disturbance 0.9 0.9 1.9 0.0 15.9 0.0 21.5 15.9 0.0 0.9 0.9 15.9 25.2 
Hyperactivity 2.4 2.4 0.0 0.0 12.2 2.4 22.0 14.6 0.0 2.4 2.4 14.6 24.4 
Signs of Peripheral Neuropathy 1.4 1.4 2.7 0.0 14.9 0.0 23.0 14.9 1.4 1.4 1.4 17.6 20.3 
Seizure 2.4 0.0 2.4 2.4 16.7 0.0 21.4 16.7 0.0 2.4 0.0 11.9 23.8 
Self-Hug 1.1 1.1 2.2 0.0 16.5 0.0 24.2 16.5 0.0 1.1 1.1 14.3 22.0 
Hypotnia 1.3 1.3 2.6 0.0 18.4 0.0 22.4 18.4 1.3 0.0 0.0 13.2 21.1 
Craniofacial Abnormalities 1.0 1.0 3.9 1.0 15.7 1.0 21.6 15.7 1.0 0.0 1.0 14.7 22.5 
Eye Abnormalities 1.4 1.4 2.9 0.0 15.7 0.0 21.4 17.1 1.4 1.4 1.4 14.3 21.4 
Ear Abnormalities 1.7 1.7 1.7 0.0 13.3 0.0 21.7 13.3 1.7 1.7 0.0 18.3 25.0 
Ear Infections 1.5 0.0 2.9 0.0 22.1 0.0 17.6 20.6 0.0 0.0 0.0 16.2 19.1 
Hearing Loss 2.4 0.0 4.8 0.0 19.0 0.0 16.7 19.0 2.4 0.0 0.0 16.7 19.0 
Oral/Motor Dysfunction 1.9 1.9 1.9 0.0 16.7 0.0 20.4 16.7 1.9 0.0 0.0 16.7 22.2 
Cleft Lip/Palate  0.0 14.3 0.0 0.0 0.0 0.0 28.6 0.0 0.0 0.0 0.0 14.3 42.9 
Dental Anomalies 0.0 5.0 5.0 0.0 15.0 0.0 20.0 15.0 0.0 0.0 0.0 15.0 25.0 
Hoarse Voice 1.4 1.4 1.4 0.0 16.9 1.4 18.3 16.9 0.0 0.0 1.4 18.3 22.5 
Hypercholestorlemia 0.0 3.7 0.0 0.0 14.8 0.0 22.2 14.8 0.0 0.0 3.7 11.1 29.6 
Digestive Problems 2.6 2.6 0.0 0.0 15.8 0.0 21.1 15.8 2.6 0.0 2.6 13.2 23.7 
Overweight 0.0 0.0 3.7 3.7 16.7 0.0 24.1 16.7 0.0 0.0 0.0 14.8 20.4 
Short Stature 0.0 3.0 3.0 0.0 12.1 3.0 24.2 12.1 0.0 0.0 3.0 9.1 30.3 
Scoliosis 0.0 4.8 0.0 0.0 14.3 0.0 19.0 14.3 0.0 0.0 0.0 14.3 33.3 
Heart Defect 0.0 4.3 4.3 0.0 13.0 4.3 21.7 13.0 0.0 0.0 0.0 17.4 21.7 
Kidney Abnormality 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
Breathing Problem 6.3 6.3 0.0 0.0 12.5 0.0 12.5 12.5 0.0 0.0 0.0 18.8 31.3 
AbnGait 2.3 2.3 2.3 0.0 14.0 0.0 23.3 14.0 0.0 0.0 2.3 14.0 25.6 
AidScho 0.0 2.9 2.9 0.0 14.3 0.0 22.9 14.3 0.0 0.0 2.9 11.4 28.6 
App 2.4 2.4 2.4 0.0 16.7 0.0 19.0 16.7 0.0 2.4 0.0 19.0 19.0 
AskRef 4.5 0.0 4.5 0.0 13.6 0.0 22.7 13.6 0.0 0.0 4.5 13.6 22.7 
Bedwet 2.9 0.0 2.9 0.0 20.6 0.0 20.6 20.6 0.0 0.0 0.0 14.7 17.6 
ChApp 3.3 3.3 0.0 0.0 13.3 0.0 20.0 13.3 0.0 3.3 0.0 16.7 26.7 
CoHand 5.9 5.9 0.0 0.0 11.8 0.0 17.6 11.8 0.0 0.0 0.0 17.6 29.4 
DecrEx 0.0 7.1 7.1 0.0 7.1 0.0 28.6 7.1 0.0 0.0 7.1 14.3 21.4 
DelTT 0.0 4.3 0.0 0.0 13.0 0.0 26.1 13.0 0.0 0.0 0.0 8.7 34.8 
Diab 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
DifShoe 5.0 0.0 5.0 0.0 15.0 0.0 20.0 15.0 0.0 0.0 5.0 15.0 20.0 
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Phenotype 
A3
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4G
 
A4
68
5G
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G
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G
31
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G
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T 
G
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23
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DrySkin 2.6 0.0 0.0 0.0 15.8 0.0 21.1 15.8 0.0 2.6 2.6 13.2 26.3 
ElLim 0.0 10.0 0.0 0.0 10.0 0.0 20.0 10.0 0.0 0.0 0.0 10.0 40.0 
FavFood 4.2 0.0 0.0 0.0 16.7 0.0 25.0 16.7 0.0 0.0 0.0 12.5 25.0 
FdNotEat 3.6 0.0 0.0 0.0 10.7 0.0 25.0 10.7 0.0 3.6 3.6 14.3 28.6 
Folic 0.0 0.0 5.6 0.0 11.1 0.0 33.3 11.1 0.0 0.0 5.6 11.1 22.2 
FruCom 3.2 0.0 0.0 0.0 12.9 0.0 22.6 12.9 0.0 3.2 3.2 16.1 25.8 
HLFood 2.8 0.0 2.8 0.0 16.7 0.0 22.2 16.7 0.0 2.8 0.0 16.7 19.4 
LUHand 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 0.0 0.0 66.7 
MusCram 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 33.3 0.0 33.3 
MusWeak 0.0 7.7 7.7 0.0 7.7 0.0 30.8 7.7 0.0 0.0 0.0 15.4 23.1 
NmlApp 3.0 0.0 0.0 0.0 12.1 0.0 24.2 12.1 0.0 3.0 3.0 15.2 27.3 
NmlIQ 0.0 0.0 0.0 0.0 20.0 0.0 20.0 20.0 0.0 0.0 0.0 20.0 20.0 
NTD 0.0 0.0 0.0 0.0 25.0 0.0 25.0 25.0 0.0 0.0 0.0 0.0 25.0 
OCD 2.6 2.6 2.6 0.0 10.5 0.0 23.7 10.5 0.0 2.6 2.6 18.4 23.7 
Pplan 0.0 3.1 3.1 0.0 15.6 0.0 21.9 15.6 0.0 0.0 3.1 15.6 21.9 
Prog 0.0 2.6 0.0 0.0 15.4 0.0 17.9 15.4 0.0 0.0 2.6 17.9 28.2 
PrRegFo 2.9 0.0 2.9 2.9 11.8 0.0 26.5 11.8 0.0 2.9 2.9 14.7 20.6 
School 2.2 2.2 2.2 0.0 13.0 0.0 23.9 13.0 0.0 2.2 2.2 13.0 26.1 
ShHand 0.0 2.1 2.1 0.0 14.9 2.1 21.3 12.8 2.1 0.0 2.1 14.9 25.5 
SignLan 5.0 0.0 0.0 0.0 15.0 0.0 25.0 15.0 0.0 0.0 0.0 10.0 30.0 
Situp 0.0 0.0 0.0 0.0 0.0 0.0 50.0 0.0 0.0 0.0 0.0 25.0 25.0 
SkVeAbn 0.0 20.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 20.0 40.0 
Speak 0.0 0.0 6.3 0.0 18.8 0.0 25.0 18.8 0.0 0.0 0.0 12.5 18.8 
SpScho 2.0 2.0 2.0 0.0 14.3 0.0 20.4 14.3 0.0 2.0 2.0 14.3 26.5 
Stand 0.0 0.0 0.0 0.0 20.0 0.0 20.0 20.0 0.0 0.0 0.0 20.0 20.0 
Stdonown 0.0 0.0 0.0 0.0 0.0 0.0 25.0 0.0 0.0 25.0 0.0 25.0 25.0 
Step 0.0 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 33.3 0.0 33.3 
Syn 0.0 1.8 5.4 0.0 14.3 0.0 23.2 16.1 0.0 0.0 0.0 12.5 26.8 
Tsyn 0.0 0.0 11.1 0.0 22.2 0.0 22.2 22.2 0.0 0.0 0.0 11.1 11.1 
 
